TTrialPathMatch Me to Trials
← Back to trials
RecruitingAdvanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Eligible age

18+ yrs

Accepts

All genders

Locations

9 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

Sponsor: Blueprint Medicines Corporation

You may qualify if…

  • ✓ 1. Pathologically confirmed diagnosis of metastatic Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) with evidence of a single KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA).
  • ✓ 2. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • ✓ 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
  • ✓ 4. Patients must have received all standard therapies for their cancer type in the metastatic setting, unless they are unable to receive such therapies due to clinical characteristics, comorbidities, or other medically justified reasons.

You may not qualify if…

  • ✕ 1. History of additional malignancy within the last 2 years, with some exceptions as specified in the protocol.
  • ✕ 2. Active brain metastases (participants with asymptomatic brain metastases may be eligible).
  • ✕ 3. Have received prior targeted treatment(s) against KRAS, including pan-KRAS inhibitors, multi-RAS inhibitors, mutant-selective KRAS inhibitors, and RAS or KRAS degraders.
  • ✕ 4. Active or uncontrolled systemic infection, such as tuberculosis, Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV).
  • ✕ The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it's recruiting

Florida

Sarasota · Tampa

Louisiana

Baton Rouge

Michigan

Ann Arbor

New Jersey

Hackensack

New York

New York

Tennessee

Nashville

Texas

Houston

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT07629960 · last updated 2026-09-21

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors · TrialPath